Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Consensus Recommendation of “Buy” from Brokerages

Siemens Healthineers AG (OTCMKTS:SMMNY) has been given an average rating of “Buy” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and three have issued a strong buy rating on the company.

A number of analysts have issued reports on SMMNY shares. Sanford C. Bernstein upgraded shares of Siemens Healthineers to a “strong-buy” rating in a research note on Tuesday, January 13th. Deutsche Bank Aktiengesellschaft lowered shares of Siemens Healthineers from a “buy” rating to a “hold” rating in a research note on Thursday, December 4th. Royal Bank Of Canada started coverage on shares of Siemens Healthineers in a report on Wednesday, December 17th. They issued a “moderate buy” rating for the company. Zacks Research raised shares of Siemens Healthineers from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Citigroup reiterated a “buy” rating on shares of Siemens Healthineers in a report on Friday, January 23rd.

Siemens Healthineers Price Performance

SMMNY opened at $21.24 on Thursday. The stock’s 50-day moving average price is $24.11 and its 200 day moving average price is $25.72. Siemens Healthineers has a 12-month low of $20.85 and a 12-month high of $28.92.

About Siemens Healthineers

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.